DNA transfection and other techniques have identified a class of dominant transforming genes from human and rodent tumour cells. Many of these transforming genes are the cellular homologues of acutely transforming viral oncogenes and are referred to as cellular oncogenes or proto-oncogenes. There are now more than 30 cellular oncogenes or protooncogenes. This class of gene has a physiological role in the regulation of cellular proliferation of differentiation. The designation proto-oncogene implies that these normal cellular genes need to be activated before they act in neoplasms. Their relevance as prime movers in the cancer process, however, is unconfirmed. 9 Based on the viral model, the cellular Ha-ras oncogene (c-Ha-ras) was thought to be a potential cancer gene because it encodes a 21 000 dalton protein, p21ras which is colinear with the oncogene product p21 of Ha-MuSV. The c-Haras from the bladder carcinoma cell line differs from its normal cellular counterpart in a point mutation in exon 1, which changes the 12th amino acid of p21r,, from glycine to valine.9 This mutation does not cause overproduction of the ras gene product (p21), nor does it change its affinity for GTP/GDP binding or the cellular location of ras protein. 22 The intrinsic hydrolysing activity of mutated ras protein, however, is about 10-fold lower than that of normal p21. 23 This change was thought to activate this gene to the functional equivalent of Ha-MuSV.
c-Ha-ras mutated at codon 12, has also been found in a high proportion of mammary carcinomas in rats induced by nitrosomethylurea.24 Mouse skin tumours, including premalignant papillomas induced by chemicals, also showed mutations at codon 61 of c-Ha-ras. The prevalence of this mutation depended on the initiation agent used, but not the promotor, and the mutation was heterozygous in most papillomas but homozygous or amplified in some carcinomas.25 These results suggested that mutation of c-Ha-ras occurs at the step of initiation, and further chromosomal changes at this locus may occur during tumour progression. 25 Other members of the ras gene family also transform NIH 3T3 cells. c-Ki-ras, the cellular homologue of the ras gene of Kirsten sarcoma virus and N-ras, which is related to both Harvey and Kirsten sarcoma viruses, transform NIH 3T3 cells. Both c-Ki-ras and N-ras encode a p21 protein that is related to the product of c-Ha-ras. Mutation at codon 12 of c-Ki-ras is relatively common,26 while N-ras is usually mutated at codon 61 Chan, McGee types were observed beyond those induced by ras alone, but cotransfection with large T and ras genes induced transformants which produced rapidly growing tumours in nude mice. The two oncogenes combined achieved complete conversion to tumourigenicity. Mutated ras can also cooperate with the early gene of adenovirus (Ela) to induce transformant foci. 40 The conversion of a normal cell into a tumour cell can thus be achieved by the cooperation of two distinct oncogenes, one cellular and one viral.
In some cases of B cell lymphomas and American Burkitt's lymphoma an apparently activated myc gene has been found, together with oncogenes such as B lym'6 and N-ras. 26 
Biological activity of cellular oncogenes
Based on biological activity, oncogene products are classified into several groups that are analogous to components of the mitogenic pathway, such as growth factors, membrane receptors, signal transducing proteins and nuclear proteins. Deregulation results in stimulation of growth or phenotypic change, or both.
Protein products of some oncogenes stimulate secretion of growth factors. Cells transfected by some oncogenes (such as ras, src, middle T, mos, fes, abl, fps, erb B, yes and mil/raf) release growth stimulating factors. 42 The growth factors are not encoded by the oncogenes themselves but by quite separate genes whose expression is indirectly stimulated by transfected oncogene. Some oncogenes, such as c-sis,43 encode growth stimulatory proteins, and if deregulated, may assume the status of active oncogenes. Irrespective of whether increased secretion of growth factors is due to stimulation by oncogene products or by their direct transcription, cells must display the corresponding receptors on the cell membrane before a closed, positive feedback loop can be established. The establishment of these loops provides cells with a steady stream of growth stimulatory signals and frees them from dependence of growth factors imported from elsewhere.
Cellular oncogenes in neoplasia
Deregulation of the receptors of growth factors can also activate the mitogenic pathway. Here, the receptors themselves are changed in a way which continuously bombards the cell with growth stimulatory signals, even in the absence of growth factors. In this way the growth factor receptor assumes the role of an oncogenic protein. Three examples of this type have been reported. The first came from the work on the epidermal growth factor (EGF) receptor. 44 Sequencing of a portion of this receptor showed near identity with the protein specified by the erb B oncogene from the avian erythroblastosis virus.
The mitogenic pathway can also be activated by deregulation of proteins within the cells that transduce signals from growth factor receptors to targets further downstream. Ras proteins are good candidates as transducers of signals from cell surface receptors to intracellular targets because of their intrinsic GTP/GDP binding and hydrolysing activity. The GTPase activity of mutated c-Ha-ras is about 10 times lower than that of its normal counterpart.23 When GTP binds to ras protein, it is activated to an excited state and sends out stimulatory signals to targets downstream. Stimulation stops on hydrolysis of GTP to GDP. Decreased GTPase activity of mutated ras protein may prolong its half life in the excited state, or the steady state concentration of p21 "aY-GTP complex, or both, resulting in continuous signals. In this way the mitogenic pathway can be activated continuously, even when the stimulation of surface receptors is terminated. The EGF receptor also stimulates nucleotide binding by p2lras. Ras protein stimulates the growth promoting effect of a variety of growth factors by stimulating inositol phospholipid metabolism, which participates in the signal transducing pathway. The growth promoting effect of EGF, however, which is independent of inositol phospholipid turnover, is also stimulated by ras proteins. 45 The exact mechanism of growth stimulation by mutated ras protein is still obscure.
Some oncogene proteins are located in the nucleus and these may have a role in growth control. The Ela oncogene of human adenovirus is a transacting regulator of transcription of other viral and cellular genes.46 Cells transfected with myc oncogenes have an increased ability to promote expression of resident cellular genes as well as introduced genes, such as heat shock protein genes.47 Myc protein may perturb the activity or specificity of the cellular transcription apparatus and mobilise the expression of a bank of cellular genes whose protein products are critical for growth and differentiation. 47 The normal cell genome carries multiple oncogenes whose products are nuclear (c-myc, N-myc, myb, fos, p53 and ski). Each of the proteins encoded by these genes may activate a slightly different group of cellular genes, but the 1059 abilities of most of them to affect transcription have yet to be shown. Growth factors also stimulate expression of myc, fos, and p53.
Cellular oncogenes in human neoplasms
The role of oncogenes in real human cancers has been examined by three quite different methods applied to experimental systems: transfection assays; DNA, mRNA blots, and in situ hybridisation; immunohistochemical demonstration of oncogene products. Some of the data relating to cellular oncogene activation in human neoplasms are summarised below. c-Ha-ras mRNA is present not only in malignant and benign epithelium but also in the stromal supporting cells (fibroblasts, endothelial cells, and smooth muscle cells of blood vessels) in mammary disease (fig  1-3) . Immunohistochemically, ras p21 has been shown in normal mammary acini but it is not yet clear whether this is a c-Ha, N, or Ki-ras product.50 In experimental mouse mammary tumours c-Ha-ras is also expressed by the same cell types but the stromal and epithelial cells of the overlying skin do not express it (fig 3) . Although it is clear that c-Ha-ras expression is not an exclusive property of cancer cells in vivo, the presence of c-Ha-ras mRNA in stromal supporting cells of breast tumours raises intriguing questions. Additionally, these data (figs 1-3) underline the importance of combined molecular and cellular localisation data. If the nucelic acid extraction data (Chan VTW, McGee JO'D, unpublished observations) in this study were looked at in isolation, the erroneous assumption could be made that oncogene expression is a result of epithelial cell activity only. I) was due to c-Ha-ras mRNA. This point has general relevance to all studies in oncogenes.
Amplification of c-myc and non-germ line c-mycrelated fragments occur in some breast cancer biopsy specimens and c-myc transcripts were raised in 10 of 14 cases. Of these 10 tumours, the c-myc gene was amplified in six cases. There was no correlation between genetic change of the c-myc domain and the level of mRNA.i0 In a separate study 87% of cancers and 43% of benign lesions had raised c-myc mRNA.49 In the latter study N-ras (73%) and Ki-ras (65%) were also expressed in breast cancer and in about 30% of benign lesions. Expression of these cellular oncogenes, therefore, like c-Ha-ras, is not an exclusive property of malignant tumours.
A rare restriction fragment length polymorphism (RFLP) of c-mos has been found often in patients with breast cancers, and it was postulated that these patients have a particular susceptibility to breast cancer. 5 1 Cellular oncogenes in neoplasia Krontiris et al reported that the percentage of rare allelic lengths of c-Ha-ras is higher in patients with various tumours than that in controls, and they concluded that unusual alleles may be associated with susceptibility to cancer."2 We have found no unusual alleles in breast cancers (Chan VWT, McGee JO'D, unpublished observations).
Recently amplification of the cellular protooncogene neu has been correlated with a bad prognosis, when prognosis is measured with time to relapse and overall survival.53 It has been claimed that amplification of neu is more important than tumour size, patient age, and receptor status, and is independent of axillary node metastasis. If these observations are confirmed they will have considerable clinical relevance for biopsy diagnosis. LUNG c-myc, N-myc, and c-Ki-ras are amplified in some human lung cancers. In 41 patients54 c-myc and Nmyc were at high (> 3 copies/haploid genome) or medium levels (1 %53 copies/haploid genome). A quite separate myc gene (L-myc) is amplified in small cell carcinomas of lung (SCCL), but this occurs in only about 10% of samples analysed.55 This gene was also expressed in these lung tumours and cell lines with amplified L-myc, but one cell line without an amplified gene also showed L-myc transcripts. c-myc amplification was initially thought to be associated with an aggressive histopathological tumour type16 but this is in doubt.54 COLON In colonic cancers activated c-Ki-ras and N-ras were found in four of 28 cases.33 c-Ha-ras has also been implicated in colonic cancers. Nine of 17 primary colonic cancers had substantially raised concentrations ofras protein compared with adjacent normal tissue. There was no correlation between ras p21 and tumour stage or metastases; in fact, the reverse was found. Eight of the nine ras positive tumours were Dukes' B or C, while Dukes' "D" (four of five cases) had normal concentrations. In metastatic deposits all nine cases showed considerably reduced concentrations of p21. These findings were interpreted as indicating that p21 plays a part in the early stages of colonic cancer but that it is not essential for tumour progression and spread.56 This is supported by the observation that both c-Ha and c-Ki-ras are expressed at high concentrations in premalignant colonic polyps.57
LYMPHOMA AND LEUKAEMIA c-abl expression is typical of CLL. The novel abl transcript in CLL is induced by a t(9-22) translocation27 and seems to be specific for this leukaemia as it has only been found in one of 25 other leukaemic 1061 patients.26 This is strong evidence that these abl transcripts have a role in the genesis of CLL.
In a relatively comprehensive analysis of oncogene expression in acute lymphocytic leukaemia c-myc and c-myb were detected in all cases at variable concentrations. No correlation, however, was observed between rates of transcription and cell proliferation, or stage of differentiation. Conversely, significant amounts of c-fos transcription were detected only in myelomonocytic and monocytic leukaemia; c-Ha-ras was uniformally expressed at low levels in neoplastic and non-neoplastic white blood cells; c-Ki-ras expression was found only in T ALL, while N-ras transcription was barely detected. 58 In addition to c-myc activation and translocation in Burkitt's lymphoma, this gene is also translocated (t8-14) in some cases of acute lymphocytic leukaemia (ALL). In ALL, high concentrations of two different c-myc transcripts were detected and these differed in size from normal c-myc mRNA. In transfection assays activated N-ras, mutated at codon 13, has also been described in acute myelogenous leukaemia.
TUMOURS OF OTHER SYSTEMS
In spite of the fact that mutated c-Ha-ras was identified in a bladder cancer cell line (EJ/T24) only two of 23 urinary tract tumours contained transforming DNA. In one case ras was mutated at codon 61, while in the other neither codon 12 nor 61 were mutated.
Striking amplification of the N-myc gene occurs in neuroblastoma. In 12 of 63 cases the amplification was 100 to 300-fold and three to 10-fold in a further 10 cases. Amplification is highly correlated with disease stage-that is, all 24 cases with N-myc amplification were stage 3-4.59 In retinoblastomas N-myc is expressed at high concentrations, but this does not invariably correlate with N-myc amplification. 60 Other cellular oncogene anomalies have been recorded in a variety of tumours, such as c-erb-2 in salivary tumours, c-raf in gastric cancers, and mutated c-Ki-ras in ovarian cancer.
Amplification or deletion, or both, of oncogenes occur in some human tumours.61 In 101 tumours from different sites no detectable amplification of cHa-ras was observed, but there was apparent loss of one c-Ha-ras allele in some. On average, about 18% showed allelic deletion, and this was twice as common in metastases (29%) as in primary tumours (15%). Deletion of c-myb was also observed in some tumours. The average percentage of tumours having c-myb deletion was 1 % but there was no difference between primary and metastatic tumours. In contrast, amplification of c-myc was observed in 10% of these 
